Page 21 - Peter Stein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Billy Dunn, FDA official in charge of neuroscience drug reviews, to leave agency

BioPharma

Rd al sandrockPeter steinTeresa buracchioBrian abrahamsBilly dunnBrian skorneyOffice of new drugsDivision of neurological productsReata pharmaceuticalsDrug administrationOffice of neuroscienceNational institute of neurological disordersNational instituteNeurological disordersNeurological productsStat news

Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

/PRNewswire/ Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney.

United kingdomUnited statesPeter steinAkebia therapeutics incExchange commissionOffice of new drugsEuropean medicines agencyDrug administrationFormal dispute resolution requestComplete response letterNew drugsDrug evaluationSenior advisorNew drug applicationAkebia therapeuticsSecurities litigation reform act

Akebia Therapeutics (AKBA) Receives Interim Response from the FDA to Appeal for Vadadustat

Akebia Therapeutics (AKBA) Receives Interim Response from the FDA to Appeal for Vadadustat
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Peter steinOffice of new drugsDrug administrationFormal dispute resolution requestComplete response letterNew drugsDrug evaluationSenior advisor

Rare Disease Expertise On FDA Advisory Committees Gains Capitol Hill Attention

Rare Disease Expertise On FDA Advisory Committees Gains Capitol Hill Attention
informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.

Peter steinPatrizia cavazzoniSee centerDrug administrationCentral nervous system drugs advisory committeeAdvisory committeeBiogen incOffice of new drugsAdvisory committee meetings likely to remain virtualRare disease programPink sheetNew drugsNew drugs director peter steinExcellence not best model forDisease programBudget draft

America s Stake in Hong Kong

(Archived document, may contain errors) No. 137 October 2, 1995 AMERICA'S STAKEINHONGKONG

United statesHong kongUnited kingdomUnited states information agencyDistrict of columbiaHong kong special administrative regionHong kong generalJohnt doriUs hong kongAmerica hong kongThomasp sheehyPeter steinRichardd fisher jrChris yeungJardines mathesonBryant johnson